Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04653740 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

Study acronym: OMERIC
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jun 2026 → Oct 2026
See other at-risk trials from Centre Oscar Lambret

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 2026 to Oct 2026 Show 4 more changesShow less
    • Study completion pushed from Jun 2026 to Nov 2027
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study description expanded, about 6 words
  2. Primary and study completion dates: Sep 2025 to Jun 2026
    • Site details revised
    v3
  3. Primary and study completion dates: Sep 2023 to Sep 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a monocentric cohort study, prospective and interventional with minimal risks and constraints for advanced breast cancer. The planned interventions are collection of biological samples at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib treatment with a clinical-biological database.
Trial Details
NCT Number NCT04653740
Lead Sponsor Centre Oscar Lambret
Collaborators: Laboratoire PRISM - Michel SALZET
Conditions
(from sponsor)		 Advanced Breast Cancer
Related terms Breast Neoplasms
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov